Patents by Inventor Hyeong-Wook Choi

Hyeong-Wook Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11136335
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides or analogs thereof through a cyclization reaction strategy. The strategy of the present invention involves subjecting an intermediate to Prins reaction conditions to afford a macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides or analogs thereof and methods for preparing the same.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 5, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Hyeong-Wook Choi, Atsushi Endo, Francis G. Fang, Dae-Shik Kim
  • Publication number: 20210205348
    Abstract: Provided herein are methods for the treatment of bladder cancer.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 8, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Publication number: 20210188867
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Applicants: EISAI R&D MANAGEMENT CO., LTD., EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE, Jaemoon LEE
  • Publication number: 20210171555
    Abstract: We provide diastereomerically pure or substantially diastereomerically pure activated phosphoramidochloridate morpholino nucleosides, methods of their preparation, and methods of their use in stereospecific coupling for stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs).
    Type: Application
    Filed: October 28, 2020
    Publication date: June 10, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi ENDO, Robert T. YU, Francis FANG, Hyeong Wook CHOI, Mingde SHAN
  • Patent number: 11028119
    Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 8, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hyeong-wook Choi, Steven Mathieu, Frank Fang, Bryan Matthew Lewis
  • Publication number: 20210137936
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: September 25, 2020
    Publication date: May 13, 2021
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun HUANG, Hyeong Wook CHOI, Kristen SANDERS, Steven MATHIEU, Arani CHANDA, Francis FANG
  • Patent number: 10981929
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides or analogs thereof through a cyclization reaction strategy. The strategy of the present invention involves subjecting an intermediate to Prins reaction conditions to afford a macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides or analogs thereof and methods for preparing the same.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 20, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Hyeong-Wook Choi, Atsushi Endo, Francis G. Fang, Dae-Shik Kim
  • Patent number: 10941148
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: March 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Patent number: 10934307
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: March 2, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
  • Patent number: 10913749
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: February 9, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase
  • Publication number: 20210017163
    Abstract: Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 21, 2021
    Inventors: Kevin Wayne KUNTZ, Hyeong Wook CHOI, Steven MATHIEU, Kristen SANDERS, Arani CHANDA
  • Patent number: 10836784
    Abstract: A phosphoramidochloridate morpholino monomer of the following formula is provided:
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: November 17, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Atsushi Endo, Robert T. Yu, Francis Fang, Hyeong Wook Choi, Mingde Shan
  • Patent number: 10821113
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 3, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Publication number: 20200331928
    Abstract: The invention provides methods utilizing Prins reaction in the preparation of compounds that may be useful as intermediates in the synthesis of halichondrin macrolides and analogs thereof. The invention also provides compounds that may be useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.
    Type: Application
    Filed: January 3, 2019
    Publication date: October 22, 2020
    Inventors: Hyeong-Wook CHOI, Francis G. FANG
  • Patent number: 10793581
    Abstract: The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: October 6, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. Fang, Hyeong-wook Choi, Silvio Campagna, Steven Mathieu
  • Publication number: 20200299321
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 4, 2020
    Publication date: September 24, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Publication number: 20200223864
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Application
    Filed: March 30, 2020
    Publication date: July 16, 2020
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE, Jaemoon LEE
  • Patent number: 10710987
    Abstract: Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: July 14, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Hyeong Wook Choi, Steven Mathieu, Kristen Sanders, Arani Chanda
  • Publication number: 20200123189
    Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 23, 2020
    Inventors: Hyeong-wook Choi, Steven Mathieu, Frank Fang, Bryan Matthew Lewis
  • Publication number: 20200115405
    Abstract: A method of preparation of stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs) of one of the following general formulas is provided.
    Type: Application
    Filed: September 17, 2019
    Publication date: April 16, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi ENDO, Robert T. YU, Francis FANG, Hyeong Wook CHOI, Mingde SHAN